Literature references Sample Clauses

Literature references. For addi- tional background information on this test guideline, the following references should be consulted:
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Literature references. F o r a ddi- t io n a l b a c k g r o un d i nfo r m a t io n o n t h i s t es t g u ideli n e, t h e followi n g r efe r e n ces s h o u ld be co n s u l t ed:
Sample 1Sample 2
Literature references. 1. Xxxxxxxxx XX, Xxxxxxxx I, Xxxxx XX, Xxx M, Xxxxxx XX, Xxxxxxxxx N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 2014: Issue 1. Art. No.: CD009593.
Sample 1
Literature references. 2 Emos G. et al., Efficacy and safety of AEZS-108 (INN: Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago- study group (AGO GYN 5), Gynecol Oncol 2014 Jun, 133 (3): 427-32 3 Emons G, Xxxxx S, Xxxxxx P, Xxxxxxx J, Wimberger P, Xxxxxxx A, Xxxxxx XX, Xxxxxxx F, Xxxx P, Gruendker C, AGO Study Group. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor- positive platinum resistant ovarian cancer. J Clin Oncol 2010 ASCO Annual Meeting Proceedings;28(15s):abstract 5035.
Sample 1
Literature references. 1 Xxxxxxxxx XX, Xxxxxxx AV, Xxxxx M, Xxxx AM, Xxxx A, Xxxxxxxxxx K, Xxxxxxxxx A Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectivenessInt. J. Oncology 2001; 19:571-7
Sample 1

Related to Literature references

  • Cross-References References in this Amendment to any Part or Subpart are, unless otherwise specified, to such Part or Subpart of this Amendment.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

Time is Money Join Law Insider Premium to draft better contracts faster.